AxoGen stock price target lowered to $20 by Raymond James on BLA timing

Investing.com - Raymond (NSE:RYMD) James has lowered its price target on AxoGen, Inc. (NASDAQ:AXGN) to $20.00 from $21.00 while maintaining an Outperform rating on the stock. According to InvestingPro data, the company has demonstrated strong momentum with a 61% return over the past year, while analyst targets range from $21 to $30.

The firm noted that AxoGen’s second-quarter results showed improved momentum with better revenue growth and gross margin performance compared to previous periods. InvestingPro data reveals an impressive gross margin of 74.18% and robust revenue growth of 18.81% over the last twelve months.

Raymond James indicated that while the low end of AxoGen’s second-half guidance suggests a potential growth deceleration, they view this outlook as conservative given recent trends and expected contributions from newly added representatives.

The company’s Biologics License Application (BLA) remains on track for potential approval in early September, which Raymond James considers an important de-risking event for both the company and its stock.

Despite acknowledging investor caution ahead of the regulatory decision, Raymond James expressed confidence in the data and approval process, stating that AxoGen’s growth profile justifies a higher stock price, supporting their continued Outperform rating.

In other recent news, AxoGen Inc. reported impressive financial results for the second quarter of 2025. The company announced an adjusted earnings per share of $0.12, which is double the anticipated $0.06. AxoGen’s revenue also surpassed expectations, reaching $56.7 million compared to the forecasted $52.66 million. These strong earnings and revenue figures highlight the company’s robust performance. Following these results, Jefferies raised its price target for AxoGen to $25.00 from $24.00, while maintaining a Buy rating. The increase in the price target is attributed to the company’s second-quarter sales results, which exceeded consensus estimates by approximately 8%. The sales growth was noted to be in double digits across all markets, indicating a strong market presence. These developments reflect positive investor sentiment towards AxoGen’s recent performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.